Vivus Obesity Drug Cut Weight 10 Percent
Posted on: Wednesday, 10 May 2006, 12:06 CDT
Vivus said Wednesday it has seen positive findings from phase 2 studies of its new oral obesity treatment Qnexa.
The company said its placebo-based trial involving 200 patients taking Qnexa showed more than 50 percent of patients taking Qnexa experienced a 10-percent or greater total body weight loss over 24 weeks.
The trial, conducted at Duke University Medical Center, also showed treated patients had a mean weight loss of 25.1 pounds, compared to 4.8 pounds in patients on placebo.
Vivus also said the weight of patients given Qnexa did not plateau by the end of the study.
Qnexa was well-tolerated, with a study completion rate of 92 percent vs. 62 percent for the placebo group, the company said.
Qnexa is being developed as a proprietary pharmaceutical treatment that incorporates the active ingredients from two previously approved products with demonstrated weight loss properties, said Wesley Day, Vivus' vice president of clinical development. We believe that by combining the activity of each of these compounds, Qnexa simultaneously addresses the two main mechanisms that impact eating behavior.
Those mechanisms are excessive hunger and the inability to feel satisfied, he said.
Source: United Press International
Related Articles
- TRW Announces up to 50 Percent Weight Reduction in Airbag Modules
- VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
- Probiotics up gastric-bypass weight loss
- Probiotics Help Gastric-bypass Patients Lose Weight More Quickly
- Divorce, Antidepressants, or Weight Gain/Loss Can Add Years to Your Face
- Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study
- Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated With HUMIRA(R) (Adalimumab)
- American Society of Plastic Surgeons Finds That Cosmetic Body Contouring Procedures Are Up 22% Since 2005, Dramatic Rise in Weight Loss Surgery Numbers Fuels Growth
- VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, a Novel Therapy to Treat Obesity
- New Drug Shows Promise in Helping Obese Patients Lose Weight
 |
 |
User Comments (0)
RSS Feeds